Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioXcel Therapeutics (BTAI) Non-cash Items (2022 - 2025)

BioXcel Therapeutics has reported Non-cash Items over the past 4 years, most recently at $328000.0 for Q4 2025.

  • Quarterly results put Non-cash Items at $328000.0 for Q4 2025, up 31.73% from a year ago — trailing twelve months through Dec 2025 was $328000.0 (up 31.73% YoY), and the annual figure for FY2025 was $328000.0, up 31.73%.
  • Non-cash Items for Q4 2025 was $328000.0 at BioXcel Therapeutics, down from $683000.0 in the prior quarter.
  • Over the last five years, Non-cash Items for BTAI hit a ceiling of $21.4 million in Q2 2022 and a floor of $248000.0 in Q3 2024.
  • Median Non-cash Items over the past 4 years was $3.2 million (2023), compared with a mean of $6.4 million.
  • Biggest five-year swings in Non-cash Items: crashed 98.73% in 2024 and later skyrocketed 175.4% in 2025.
  • BioXcel Therapeutics' Non-cash Items stood at $15.5 million in 2022, then crashed by 77.53% to $3.5 million in 2023, then tumbled by 92.84% to $249000.0 in 2024, then surged by 31.73% to $328000.0 in 2025.
  • The last three reported values for Non-cash Items were $328000.0 (Q4 2025), $683000.0 (Q3 2025), and $259000.0 (Q1 2025) per Business Quant data.